title: [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
abstract: Mirabegron is the first drug in a new class of oral therapy for overactive bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first time used for the treatment of urination disorders. Recently, following many years of rigorous multicenter randomized trials mirabegron has been approved for use in Europe and North America. The clinical indication for mirabegron is overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency and other storage symptoms in both men and women. Mirabegron is used in primary patients, or in patients who previously were unsuccessfully treated with anticholinergics. The drug has a good safety profile and causes no side effects typical of anticholinergics.
authors.forename: G R
authors.initials: GR
authors.lastname: Kasjan
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D064804:Urological Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000083:Acetanilides; D013844:Thiazoles; D064804:Urological Agents; C520025:mirabegron